[go: up one dir, main page]

MX2022014695A - Anti-gitr antibodies and uses thereof. - Google Patents

Anti-gitr antibodies and uses thereof.

Info

Publication number
MX2022014695A
MX2022014695A MX2022014695A MX2022014695A MX2022014695A MX 2022014695 A MX2022014695 A MX 2022014695A MX 2022014695 A MX2022014695 A MX 2022014695A MX 2022014695 A MX2022014695 A MX 2022014695A MX 2022014695 A MX2022014695 A MX 2022014695A
Authority
MX
Mexico
Prior art keywords
gitr antibodies
gitr
antibodies
methods
glucocorticoid
Prior art date
Application number
MX2022014695A
Other languages
Spanish (es)
Inventor
Frank Delfino
Dimitris Skokos
Bei Wang
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2022014695A publication Critical patent/MX2022014695A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En el presente documento se proporcionan anticuerpos y fragmentos de unión a antígeno de los mismos que se unen específicamente al receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y métodos para usarlos, incluidos, por ejemplo, métodos de tratamiento que los usan.Provided herein are antibodies and antigen-binding fragments thereof that specifically bind to the glucocorticoid-induced tumor necrosis factor receptor (GITR) and methods for using them, including, for example, treatment methods using them.

MX2022014695A 2016-06-10 2018-12-10 Anti-gitr antibodies and uses thereof. MX2022014695A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662348353P 2016-06-10 2016-06-10
US201662432023P 2016-12-09 2016-12-09
US201762500312P 2017-05-02 2017-05-02

Publications (1)

Publication Number Publication Date
MX2022014695A true MX2022014695A (en) 2022-12-16

Family

ID=59078260

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018015350A MX2018015350A (en) 2016-06-10 2017-06-09 Anti-gitr antibodies and uses thereof.
MX2022014695A MX2022014695A (en) 2016-06-10 2018-12-10 Anti-gitr antibodies and uses thereof.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018015350A MX2018015350A (en) 2016-06-10 2017-06-09 Anti-gitr antibodies and uses thereof.

Country Status (19)

Country Link
US (3) US10738126B2 (en)
EP (2) EP3468999B1 (en)
JP (2) JP7162535B2 (en)
KR (1) KR102495601B1 (en)
CN (1) CN109563170B (en)
AU (1) AU2017278193B9 (en)
BR (1) BR112018075434A2 (en)
CA (1) CA3027121A1 (en)
CL (1) CL2018003515A1 (en)
CO (1) CO2018013298A2 (en)
IL (1) IL263273B2 (en)
MA (1) MA45233A (en)
MX (2) MX2018015350A (en)
MY (1) MY200162A (en)
PH (1) PH12018502502A1 (en)
SG (1) SG11201810525XA (en)
UA (1) UA128687C2 (en)
WO (1) WO2017214548A1 (en)
ZA (1) ZA201807920B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097306A1 (en) 2013-08-20 2016-03-02 Merck Sharp & Dohme MODULATION OF TUMOR IMMUNITY
MY200162A (en) 2016-06-10 2023-12-09 Regeneron Pharma Anti-gitr antibodies and uses thereof
KR20230133934A (en) 2016-10-11 2023-09-19 아게누스 인코포레이티드 Anti-lag-3 antibodies and methods of use thereof
MX2019006734A (en) 2016-12-09 2019-10-21 Regeneron Pharma SYSTEMS AND METHODS FOR SEQUENCING T LYMPHOCYTE RECEPTORS, AND THE USES OF THEM.
EP3765503B1 (en) * 2018-03-13 2024-05-01 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
MA54945A (en) 2019-02-12 2021-12-22 Regeneron Pharma COMPOSITIONS AND METHODS OF USING B-SPECIFIC ANTIBODIES TO BIND COMPLEMENT AND TARGET ANTIGEN
RU2734432C1 (en) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Monoclonal antibody which specifically binds gitr
US20230064703A1 (en) * 2020-01-02 2023-03-02 Nanjing GenScript Biotech Co., Ltd. Anti-gitr antibodies and uses thereof
KR20210095781A (en) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 A multi-specific antibody comprising a fusion construct consisting of a Fab and a bioactive effector moiety
CA3168173A1 (en) * 2020-03-06 2021-09-10 Robert Babb Anti-gitr antibodies and uses thereof
TW202237642A (en) * 2021-01-08 2022-10-01 美商１０Ｘ基因組學有限公司 Antigen-binding polypeptides specific for coronaviruses and uses thereof
WO2022148279A1 (en) * 2021-01-08 2022-07-14 苏州丁孚靶点生物技术有限公司 Pharmaceutical product and use thereof
KR102475255B1 (en) * 2021-05-10 2022-12-09 메디맵바이오 주식회사 Anti-GITR antibodies and uses thereof
WO2023175614A1 (en) 2022-03-15 2023-09-21 Yeda Research And Development Co. Ltd. Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE69233254T2 (en) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanized Heregulin antibody
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
DE69738749D1 (en) 1996-08-16 2008-07-17 Schering Corp CELL SURFACE ANTIGEN FROM MAMMALS AND RELATED REAGENTS
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
PT1032672E (en) 1997-11-18 2009-04-02 Genentech Inc Dna19355 polypeptide, a tumor necrosis factor homolog
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1462114A1 (en) 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18)
KR20060052681A (en) 2003-05-23 2006-05-19 와이어쓰 Gitr ligand and gitr ligand-related molecules and antibody and uses thereof
US20060099171A1 (en) 2004-11-05 2006-05-11 Masahide Tone Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells
PT2343320T (en) 2005-03-25 2018-01-23 Gitr Inc Anti-gitr antibodies and uses thereof
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
US20100061984A1 (en) 2006-01-20 2010-03-11 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
SI2041177T1 (en) 2006-06-02 2012-03-30 Regeneron Pharma High affinity antibodies to human il-6 receptor
RU2448979C2 (en) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Human antibodies to delta-like human ligand-4
DK2175884T3 (en) 2007-07-12 2016-09-26 Gitr Inc Combination USING GITR BINDING MOLECULES
JO3182B1 (en) 2009-07-29 2018-03-08 Regeneron Pharma Human antibiotics with high pH generation - 2
RU2595409C2 (en) * 2009-09-03 2016-08-27 Мерк Шарп И Доум Корп., Anti-gitr antibodies
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
CN104126009B (en) 2011-10-07 2019-05-10 国立大学法人三重大学 Chimeric Antigen Receptor
KR101549637B1 (en) 2012-06-08 2015-09-03 국립암센터 Novel epitope for switching to Th1 cell and use thereof
AR097306A1 (en) 2013-08-20 2016-03-02 Merck Sharp & Dohme MODULATION OF TUMOR IMMUNITY
TW201605896A (en) * 2013-08-30 2016-02-16 安美基股份有限公司 GITR antigen binding proteins
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
MX377844B (en) 2014-05-28 2025-03-11 Agenus Inc Antibodies to the glucocorticoid-induced tumor necrosis factor receptor (GITR)-related protein and their methods of use.
PT3151921T (en) 2014-06-06 2019-11-21 Bristol Myers Squibb Co ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEIVER AND USES OF THE SAME
MX2017004311A (en) 2014-10-03 2017-12-07 Dana Farber Cancer Inst Inc Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof.
MA41044A (en) 2014-10-08 2017-08-15 Novartis Ag COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
MX382902B (en) 2014-10-31 2025-03-13 Oncomed Pharm Inc NOTH PATHWAY INHIBITOR IN COMBINATION WITH AN IMMUNOTHERAPEUTIC AGENT FOR USE IN THE TREATMENT OF CANCER.
MY200162A (en) 2016-06-10 2023-12-09 Regeneron Pharma Anti-gitr antibodies and uses thereof

Also Published As

Publication number Publication date
UA128687C2 (en) 2024-10-02
IL263273A (en) 2018-12-31
AU2017278193B9 (en) 2024-02-01
JP2022159476A (en) 2022-10-17
US11414494B2 (en) 2022-08-16
PH12018502502A1 (en) 2019-04-08
US20170355774A1 (en) 2017-12-14
MY200162A (en) 2023-12-09
EP3468999A1 (en) 2019-04-17
CN109563170A (en) 2019-04-02
ZA201807920B (en) 2024-01-31
CL2018003515A1 (en) 2019-03-08
AU2017278193A1 (en) 2018-12-13
WO2017214548A1 (en) 2017-12-14
CA3027121A1 (en) 2017-12-14
US10738126B2 (en) 2020-08-11
AU2017278193B2 (en) 2024-01-18
KR20190020297A (en) 2019-02-28
JP7162535B2 (en) 2022-10-28
KR102495601B1 (en) 2023-02-06
SG11201810525XA (en) 2018-12-28
IL263273B2 (en) 2025-10-01
IL263273B1 (en) 2025-06-01
EP4344748A3 (en) 2024-06-12
NZ748619A (en) 2024-05-31
CO2018013298A2 (en) 2019-02-19
US20230042324A1 (en) 2023-02-09
CN109563170B (en) 2023-10-13
EP4344748A2 (en) 2024-04-03
MX2018015350A (en) 2019-08-26
EP3468999B1 (en) 2024-01-10
US20210147565A1 (en) 2021-05-20
BR112018075434A2 (en) 2019-03-19
MA45233A (en) 2019-04-17
JP2019521098A (en) 2019-07-25

Similar Documents

Publication Publication Date Title
MX2022014695A (en) Anti-gitr antibodies and uses thereof.
MX381046B (en) ANTI-CSF1R ANTIBODIES AND PD-1/PD-L1 INHIBITORS, AND USES THEREOF FOR THE TREATMENT OF CANCER REFERRAL TO RELATED APPLICATIONS.
ECSP17011657A (en) DRUG CONJUGATES WITH ANTI-CDH6 ANTIBODIES
CR20160500A (en) ANTI-OX40 ANTIBODIES AND METHODS OF USE
CO2018005433A2 (en) Site-specific her2 antibody drug conjugates
MX2019006954A (en) COMBINATION THERAPY OF ANTI-CD20 / ANTI-CD3 BISPECIFIC ANTIBODIES AND 4-1BB (CD137) AGONISTS.
CR20170131A (en) ANTI-HER2 AND IMMUNOCUSED ANTIBODIES
CL2018001722A1 (en) New anti-mfi2 antibodies and methods of use (divisional application 201700506)
CO2017004516A2 (en) Humanized anti-ox40 antibodies
MX2016015614A (en) ANTI-PROTEIN ANTIBODIES RELATED TO THE RECEIVER OF THE TUMOR NECROSIS FACTOR INDICATED BY GLUCOCORTICÓIDES (GITR) AND ITS METHODS OF USE.
ECSP17034845A (en) ANTIBODY CONJUGATES - DRUG
MX2016012880A (en) Modified j-chain.
BR112017006825A2 (en) antibodies to glucocorticoid-induced tumor necrosis factor receptor (gitr) and their methods of use
MX370597B (en) USE OF A BI-SPECIFIC ANTIBODY FOR DLL3 AND CD3 IN THE TREATMENT AND PROPHYLAXIS OF CANCER.
CR20150482A (en) ANTI-B7-H4 ANTIBODIES AND IMMUNOCATION
CL2016002667A1 (en) Novel anti-rnf43 antibodies and methods for use
MX2017000985A (en) ANTI-PD-1 ANTIBODIES.
BR112017006468A2 (en) bispecific antibody, pharmaceutical composition, kit, use of a combination of a bispecific antibody and cancer treatment method
BR112016014731A2 (en) ANTI-BAFF ANTIBODIES
CO2018005393A2 (en) Anti-htra1 antibodies and methods of use thereof
CL2019002735A1 (en) Antibodies that bind to steap-1.
PE20180171A1 (en) NEUTRALIZATION OF THE CHIKUNGUNYA VIRUS MEDIATED BY ANTIBODIES
CL2016001753A1 (en) Humanized monoclonal antibody that specifically binds to netrin-1, pharmaceutical compositions and uses of the antibody for cancer treatment
MX2017001686A (en) ANTI-CERAMIDE ANTIBODIES.
MX2017012553A (en) Spirocyclic compounds.